Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Omnibus Outcomes
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
    • Research Compliance
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University School of Law
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
    • Comprehensive Support
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • 2024 Solicitation
    • Application Process
    • Entering Portfolio
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Fact Sheets
    • AMR Test Directory
  • News
    • CARB-X News
    • Recommended News
    • In the News
    • Antibiotic Resistance
    • Product Developer News
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Locus Biosciences

Locus Biosciences, Morrisville, NC, USA
www.locus-bio.com/

LBP-KP01
CRISPR CAS-3 BACTERIOPHAGE

K. pneumoniae rUTI infections

Locus Biosciences is developing a new precision medicine to treat serious recurring urinary tract infections (rUTI) caused by the bacterial pathogen Klebsiella pneumoniae. K. pneumoniae are bacteria belonging to the Enterobacteriaceae family of pathogens, and are commonly the cause of antibiotic-resistant infections in healthcare settings. LBP-KP01 is a bacteriophage cocktail that has been engineered with a CRIPSR-Cas3 construct targeting the K. pneumoniae genome. It works through a unique dual mechanism of action utilizing the natural lytic activity of the bacteriophage along with the DNA-targeting activity of CRISPR-Cas3. This dual mechanism makes LBP-KP01 significantly more effective at killing K. pneumoniae cells than corresponding natural bacteriophages. The mechanism also makes LBP-KP01 effective in killing K. pneumoniae strains regardless of whether they are resistant to antibiotics. The LBP-KP01 project is part of an arsenal of products under development by Locus designed to address serious infections irrespective of underlying drug-resistance within the species, with funding from BARDA for a bacteriophage cocktail directed against E. coli also for the treatment of UTIs

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $2.05m, with potential option payments up to $10.5m.

Initial CARB-X Investment Date: July 1, 2020

Carb-X

Led by Boston University

Copyright 2025

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2025

We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent